Results 21 to 30 of about 1,955 (223)

X-Linked Hypophosphatemia Management in Children: An International Working Group Clinical Practice Guideline [PDF]

J Clin Endocrinol Metab
Context: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children.
Abu Alrob, Hajar, Aldabagh, Rana, Alexander, R Todd, Ali, Dalal S, Alsarraf, Farah, Appelman-Dijkstra, Natasha M, Beck-Nielsen, Signe Sparre, Biosse-Duplan, Martin, Carpenter, Thomas O, Chaussain, Catherine, Crowley, Rachel K, Dandurand, Karel, de Beur, Suzanne M, Filler, Guido, Florenzano, Pablo, Friedlander, Lisa, Fukumoto, Seiji, Gagnon, Claudia, Goodyer, Paul, Grasemann, Corinna, Grimbly, Chelsey, Hussein, Salma, Imel, Erik A, Javaid, Muhammad K, Khan, Aneal, Khan, Sarah, Lehman, Anna, Lems, Willem F, Lewiecki, E Michael, McDonnell, Ciara, Mirza, Reza D, Ward, Leanne M   +31 more
core   +3 more sources

Burosumab for X-linked hypophosphataemia [PDF]

Australian Prescriber, 2021
M Whyte, T Carpenter, G Gottesman, M Mao, A Skrinar, San Martin, J   +6 more
  +4 more sources

Predictors of response to burosumab in adults with X-linked hypophosphatemia: real-world data from an Italian cohort [PDF]

J Endocrinol Invest
Purpose: X-linked hypophosphatemia (XLH) is a genetic disorder characterized by elevated FGF23 levels, leading to phosphate wasting and hypophosphatemia, causing skeletal and extraskeletal abnormalities.
Arcidiacono, Gaetano Paride, Aversa, Antonio, Brandi, Maria Luisa, Camozzi, Valentina, Campello, Elena, Cannito, Michele, Cecchinato, Alberta, Cerbone, Gaetana, D'Alessandro, Maria Michela, Diogo, Martin, Eller-Vainicher, Cristina, Fusaro, Maria, Giannini, Sandro, Girasole, Giuseppe, Guidolin, Francesca, Marcucci, Gemma, Peleg Falb, Mor, Plebani, Mario, Sella, Stefania, Simioni, Paolo, Torres, Marco Onofrio, Tripepi, Giovanni, Vezzoli, Giuseppe, Vitale, Corrado, Zampogna, Marta, Zaninotto, Martina   +25 more
core   +2 more sources

Burosumab Treatment for Autosomal Recessive Hypophosphatemic Rickets Type 1 (ARHR1)

The Journal of Clinical Endocrinology & Metabolism, 2022
Abstract Context Autosomal recessive hypophosphatemic rickets (ARHR) are rare, heritable renal phosphate-wasting disorders that arise from overexpression of the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23) leading to impaired bone mineralization (rickets and osteomalacia ...
Xiuying Bai, Mark Levental, Andrew C Karaplis   +2 more
openaire   +4 more sources

Burosumab treatment for fibroblast growth factor-23-associated hypophosphatemia in an adult patient with severe fibrous dysplasia in McCune–Albright syndrome: case report and review of the literature [PDF]

JBMR Plus
Maria Stelmachowska‐Banaś, Karolina Cylke-Falkowska, Wojciech Zgliczyński, John P. Bilezikian, Waldemar Misiorowski   +4 more
openalex   +2 more sources

Burosumab in infants with X-linked hypophosphatemic rickets: a case series [PDF]

Orphanet J Rare Dis
Ravit Regev, Avivit Brener, Nitzan Dror, Raphael Krespi, Rebeca Rapalino, Efrat Chorna, Ophir Borger, Adar Lopez, Yael Lebenthal, Leonid Zeitlin   +9 more
openalex   +2 more sources

Refractory Hypophosphatemia Secondary to Tumor-Induced Osteomalacia: Diagnostic Challenges and Successful Management With Burosumab [PDF]

Cureus
Amna Ramzan, Fahad Aftab Khan Lodhi, Farha Ramzan   +2 more
openalex   +2 more sources

Hyperparathyroidism Secondary to Burosumab Treatment [PDF]

Cureus
Nguyen, Minhtri K, Bandaru, Dhiresh, Nguyen, Minh-Kevin   +2 more
openaire   +2 more sources

Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone

Orphanet Journal of Rare Diseases, 2022
Background X-linked hypophosphatemia (XLH) is characterized by increased serum concentrations of fibroblast growth factor 23 (FGF23), hypophosphatemia and insufficient endogenous synthesis of calcitriol.
Diana-Alexandra Ertl, Justin Le Lorier, Andreas Gleiss, Séverine Trabado, Candace Bensignor, Christelle Audrain, Volha Zhukouskaya, Régis Coutant, Jugurtha Berkenou, Anya Rothenbuhler, Gabriele Haeusler, Agnès Linglart   +11 more
doaj   +1 more source

Burosumab vs phosphate/active vitamin D in pediatric X-linked hypophosphatemia: A subgroup analysis by dose level [PDF]

, 2023
CONTEXT: In an open-label, randomized, controlled, phase 3 trial in 61 children aged 1 to 12 years with X-linked hypophosphatemia (XLH), burosumab improved rickets vs continuing conventional therapy with active vitamin D and phosphate.
Biggin, Andrew, et al.,, Imel, Erik A, Whyte, Michael P   +3 more
core   +2 more sources